Safety, Efficacy, and Tolerability of Sofosbuvir and Ribavirin in Management of Recurrent Hepatitis C Virus Genotype 4 After Living Donor Liver Transplant in Egypt: What Have We Learned so far?
Dabbous, Hany M; Montasser, Iman F; Sakr, Mohamed A; Refai, Rasha; Sayam, Moataz; Ahmed, Doaa; Sayed, Hany; F Abdelghafar, Mohamed; Bahaa, Mohamed; Mahmoud El-Meteini;
Abstract
Recurrence of HCV after living donor liver transplant (LDLT) is nearly universal, with almost one third of recipients developing cirrhosis and graft failure within 5 years after LDLT. Different studies have been published on the effect of sofosbuvir after liver transplantation on recurrent HCV with different genotypes.
Other data
| Title | Safety, Efficacy, and Tolerability of Sofosbuvir and Ribavirin in Management of Recurrent Hepatitis C Virus Genotype 4 After Living Donor Liver Transplant in Egypt: What Have We Learned so far? | Authors | Dabbous, Hany M; Montasser, Iman F; Sakr, Mohamed A; Refai, Rasha; Sayam, Moataz; Ahmed, Doaa; Sayed, Hany; F Abdelghafar, Mohamed; Bahaa, Mohamed; Mahmoud El-Meteini | Keywords | Genotype 4;Liver Transplant;Sofosbuvir | Issue Date | May-2016 | Publisher | KOWSAR PUBL | Journal | Hepatitis monthly | Volume | 16 | Issue | 5 | ISSN | 1735-143X | DOI | 10.5812/hepatmon.35339 | PubMed ID | 27330537 | Scopus ID | 2-s2.0-84990303170 | Web of science ID | WOS:000378146700004 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.